PD-1/PD-L1-IN 3 ermine OC[C@H]1O[C@@H](OC2=CC3=C(C=C(O)C=C3O)[O+]=C2C2=CC(O)=C(O)C(O)=C2)[C@H](O)[C@@H](O)[C@@H]1O

OC[C@H]1O[C@@H](OC2=CC3=C(C=C(O)C=C3O)[O+]=C2C2=CC(O)=C(O)C(O)=C2)[C@H](O)[C@@H](O)[C@@H]1O

and European rights to SS734 for ophthalmic use to InSite Vision Incorporated (OTCBB: INSV) in 2000

KRN633 is a potent and selective VEGFR inhibitor

InChi: InChI=1S/C15H21N3O

PD-1/PD-L1-IN 3 ermine OC[C@H]1O[C@@H](OC2=CC3=C(C=C(O)C=C3O)[O+]=C2C2=CC(O)=C(O)C(O)=C2)[C@H](O)[C@@H](O)[C@@H]1OPD 1 PD L1 IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD 1 PD L1 and CD80 PD L1 interactions extracted from patent WO2014151634A1, compound No. 1. PD 1 PD L1 IN 3 interferes with PD L1 binding to PD 1 and CD80 by binding to PD L1, with IC50s of 5. 60 nM and 7. 04 nM, respectively. PD 1 PD L1 IN 3 can be used for the research of various diseases, including cancer and infectious diseases. Product information CAS Number: